Assessment of Risk in Chronic Airways Disease Evaluation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

767 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-05-31

Study Completion Date

2019-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with chronic obstructive pulmonary disease (COPD) have an increased risk of cardiovascular disease,osteoporosis, muscle wasting and diabetes mellitus. Cardiovascular disease is a major cause of death in such patients and it may be related to excess stiffening of the walls of major arteries, such as the aorta, and it has been suggested to represent premature aging. However, there is little known of the development of these problems, which were previously considered to be due to smoking and which is now known not to be the only factor. The investigators will study a large group of patients with mild to very severe airflow obstruction based on the NICE 2010 classification of severity and a matched comparator group free of COPD. This study involves three assessments of the development of the complications of COPD over a five year period. The key measure will be the rate of change in the aortic wall stiffness, an accepted indicator of the risk of heart disease. Changes in wall stiffness will be related to the severity of lung disease; other known cardiovascular risk factors, such as high blood pressure, increased blood cholesterol and to cardiovascular events including heart attacks and death; and to the presence of other complications, such as osteoporosis, muscle wasting and diabetes mellitus. These measures will be analysed in the context of changes in bodywide inflammation and metabolic function and the changes in the rate of ageing. This increased knowledge of interacting factors in the complications of COPD is likely to lead to studies of treatments to avoid their development.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Is COPD a Risk Factor for Cardiovascular Disease?

NCT02162095

Chronic Obstructive Pulmonary Disease

COMPLETED

Cardiovascular Risk and Chronic Obstructive Pulmonary Disease

NCT03014609

Chronic Obstructive Pulmonary Disease

RECRUITING

Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

NCT05922202

Role of Frailty in COPD

RECRUITING

Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care

NCT01516528

Pulmonary Disease, Chronic Obstructive

COMPLETED

Clinical Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure (CHF)

NCT01114386

COPD Heart Failure, Congestive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD

Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction

No interventions assigned to this group

Comparators

Current or ex-smokers free from from Respiratory Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously Proven COPD or at risk of developing COPD

Exclusion Criteria

* Pregnancy
* A history of malignancy in the last 5 years
* Unable to give informed consent or diagnosed dementia
* Renal or hepatic failure
* Active endocrine disorder eg., Addison's disease, hypothyroidism
* Any other disease identified as having an inflammatory or metabolic component, eg. rheumatoid disease
* Disorders affecting mobility, eg. Parkinson's disease, cerebrovascular accident.

Minimum Eligible Age

35 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes